Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3476 Target Snapshot

Inhibitor of nuclear factor kappa-B kinase subunit alpha · SINGLE PROTEIN · Homo sapiens

1,940Compounds
422Assays
5Approved Drugs
1,025.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt O15111. Use UniProt O15111 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O15111 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Inhibitor of nuclear factor kappa-B kinase subunit alpha as ChEMBL target CHEMBL3476, mapped to UniProt O15111. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Inhibitor of nuclear factor kappa-B kinase subunit alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3476
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O15111
Inhibitor of nuclear factor kappa-B kinase subunit alpha
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Inhibitor of nuclear factor kappa-B kinase subunit alpha is the right protein anchor across sources, using UniProt O15111 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelInhibitor of nuclear factor kappa-B kinase subunit alpha
UniProt AccessionO15111
Component TypeProtein
Sequence Length745 aa

Inhibitor of nuclear factor kappa-B kinase subunit alpha

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Inhibitor of nuclear factor kappa-B kinase subunit alpha, mapped to UniProt O15111. Sequence length is 745 aa.

Mapped IDO15111
Review nameInhibitor of nuclear factor kappa-B kinase subunit alpha
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

5
Approved
2
Phase III
4
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC50575.0
KI368.0
KD82.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL384467 9.3 IC50 0.5 Approved
CHEMBL388978 8.24 Kd 5.8 Preclinical
CHEMBL5866553 8.22 IC50 6.0 Preclinical
CHEMBL2164410 8.2 IC50 6.31 Preclinical
CHEMBL2164411 8.2 IC50 6.31 Preclinical
CHEMBL2164412 8.2 IC50 6.31 Preclinical
CHEMBL549478 8.15 IC50 7.0 Preclinical
CHEMBL558491 8.15 IC50 7.0 Preclinical
CHEMBL2164417 8.1 IC50 7.943 Preclinical
CHEMBL551773 8.1 IC50 8.0 Preclinical
Distribution

pChEMBL Value Distribution

92
5.0
124
5.5
83
6.0
56
6.5
41
7.0
30
7.5
16
8.0
0
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
SUNITINIB
CHEMBL535
Approved 2006
DEXAMETHASONE
CHEMBL384467
Approved 1958
Assay Landscape

Assay Landscape

422
Total Assays
422
Tested Compounds
3
Assay Types
Binding — 420 assays, 422 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 300 350 6.2
cell-based format 64 33 5.9
assay format 42 39 5.4
subcellular format 13 0
tissue-based format 1 0
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 0
Functional — 1 assays, 36 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 36 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine